Cardiovascular Tissue Engineering: Where We Come From and Where Are We Now?

ABSTRACT: Tissue engineering was introduced by Vacanti and Langer in the 80’s, exploring the potential of this new technology starting with the well-known “human ear on the mouse back”. The goal is to create a substitute which supplies an individual therapy for patients with regeneration, remodeling and growth potential. The growth potential of these subjects is of special interest in congenital cardiac surgery, avoiding repeated interventions and surgery. Initial applications of tissue engineered created substitutes were relatively simple cardiovascular grafts seeded initially by end-differentiated autologous endothelial cells. Important data were collected from these initial clinical autologous endothelial cell seeded grafts in peripheral and coronary vessel disease. After these initial successfully implantation bone marrow cell were used to seed patches and pulmonary conduits were implanted in patients. Driven by the positive results of tissue engineered material implanted under low pressure circumstances, first tissue engineered patches were implanted in the systemic circulation followed by the implantation of tissue engineered aortic heart valves. Tissue engineering is an extreme dynamic technology with continuously modifications and improvements to optimize clinical products. New technologies are unified and so this has also be done with tissue engineering and new application features, so called transcatheter valve intervention. First studies are initiated to apply tissue engineered heart valves with this new transcatheter delivery system less invasive. Simultaneously studies have been started on tissue engineering of so-called whole organs since organ transplantation is restricted due to donor shortage and tissue engineering could overcome this problem. Initial studies of whole heart engineering in the rat model are promising and larger size models are initiated.

Keywords: Cardiovascular System - anatomy & histology, History, 20th Century, History, 21st Century, Tissue Engineering - trends

References

1. Vacanti CA, Langer R, Schloo B, Vacanti JP, Synthetic polymers seeded with chondrocytes provide a template for new cartilage formation: Plast Reconstr Surg, 1991; 88; 753-59, pmid: 1924560

2. Shinoka T, Breuer CK, Tanel RE, Tissue engineering heart valves: valve leaflet replacement study in a lamb model: Ann Thorac Surg, 1995; 60; S513-16, pmid: 8604922

3. Nerem RM, Cellular engineering: Ann Biomed Eng, 1991; 19; 529-45, pmid: 1741530

4. Deutsch M, Meinhart J, Vesely M: J Vasc Surg, 1997; 25; 757-63, pmid: 9129636

5. Zilla P, Fasol R, Deutsch M, Endothelial cell seeding of polytetrafluoroethylene vascular grafts in humans: a preliminary report: J Vasc Surg, 1987; 6; 535-41, pmid: 3320387

6. Bradbury AW, Adam DJ, Bell J, BASIL trial Participants. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received: J Vasc Surg, 2010; 51; 18S-31S, pmid: 20435259

7. Zilla P, von Oppell U, Deutsch M, The endothelium: a key to the future: J Card Surg, 1993; 8; 32-60, pmid: 8422489

8. Deutsch M, Meinhart J, Fischlein T: Surgery, 1999; 126; 847-55, pmid: 10568184

9. Meinhart J, Halbmayer WM, Deutsch M, Zilla P, Hyperlipidemia coincides with reversible growth impairment of cultured human autologous endothelial cells: Endothelium, 2002; 9; 239-46, pmid: 12572855

10. Serruys PW, Morice MC, Kappetein APSYNTAX Investigators, Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease: N Engl J Med, 2009; 360; 961-72, pmid: 19228612

11. Dohmen PM, Pruss A, Koch C, Six years of clinical follow-up with endothelial cell-seeded small-diameter vascular grafts during coronary bypass surgery: J Tissue Eng, 2013; 4; 2041731413504777, pmid: 24020013

12. Dohmen PM, da Costa F, Yoschi S: Med Sci Monit, 2007; 13(9); BR188-93, pmid: 17767113

13. Dohmen PM, Gabbieri D, Lembcke A, Konertz W, Endothelial cell-seeded bovine internal mammary artery for complete revascularization: Ann Thorac Surg, 2007; 83; 1168-69, pmid: 17307483

14. Gosev I, Leacche M, Revascularization: the future of coronary artery bypass surgery or an unfulfilled promise?: Circulation, 2014; 130; 869-71, pmid: 25055813

15. Langer R, Vacanti JP, Tissue engineering: Science, 1993; 260; 920-26, pmid: 8493529

16. Shinoka T, Breuer CK, Tanel RE, Tissue engineering heart valves: valve leaflet replacement study in a lamb model: Ann Thorac Surg, 1995; 60; S513-16, pmid: 8604922

17. Shin’oka T, Imai Y, Ikada Y, Transplantation of a tissue-engineered pulmonary artery: N Engl J Med, 2001; 344; 532-33, pmid: 11221621

18. Shin’oka T, Matsumura G, Hibino N, Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells: J Thorac Cardiovasc Surg, 2005; 129; 1330-38, pmid: 15942574

19. Dohmen PM, Lembcke A, Hotz H, Ross operation with a tissue-engineered heart valve: Ann Thorac Surg, 2002; 74; 1438-42, pmid: 12440590

20. Dohmen PM, Lembcke A, Holinski S, Ten years of clinical results with a tissue-engineered pulmonary valve: Ann Thorac Surg, 2011; 92; 1308-14, pmid: 21958777

21. Cebotari S, Lichtenberg A, Tudorache I, Clinical application of tissue engineered human heart valves using autologous progenitor cells: Circulation, 2006; 114; I132-37, pmid: 16820562

22. Dohmen PM, da Costa F, Lopes SV, Successful implantation of a decellularized equine pericardial patch into the systemic circulation: Med Sci Monit Basic Res, 2014; 20; 1-8, pmid: 24407027

23. Dohmen PM, da Costa F, Yoshi S, Decelluarized xenografts implanted into the aortic position: J Clinic Experiment Cardiol, 2012 S: 004

24. Cebotari S, Tudorache I, Ciubotaru A, Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: early report: Circulation, 2011; 124; S115-23, pmid: 21911800

25. Zehr KJ, Yagubyan M, Connolly HM, Aortic root replacement with a novel decellularized cryopreserved aortic homograft: Postoperative immunoreactivity and early results: J Thorac Cardiovasc Surg, 2005; 130; 1010-15, pmid: 16214512

26. Baraki H, Tudorache I, Braun M, Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model: Biomaterials, 2009; 30; 6240-46, pmid: 19703713

27. Honge JL, Funder JA, Jensen H, Recellularization of decellularized mitral heart valves in juvenile pigs: J Heart Valve Dis, 2010; 19; 584-92, pmid: 21053736

28. Smit FE, Dohmen PM, Bio-artificial heart as ultimate treatment of end-stage heart failure: Med Sci Monit Basic Res, 2014; 20; 161-63, pmid: 25321347

29. Ott HA, Matthiesen TS, Goh SK, Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart: Nat Med, 2008; 14; 213-21, pmid: 18193059

30. Weymann A, Patil NP, Sabashnikov A, Bioartificial heart: A human-sized porcine model – The way ahead: PLoS One, 2014; 9; e111591, pmid: 25365554